FDA 483 - Unknown Company - January 22, 2003

This FDA Form 483 document outlines three observations made during an inspection of a facility involved in the production of sterile drug products.

Observation 1 indicates a failure to establish an adequate system for monitoring environmental conditions within the aseptic processing area. This suggests a potential risk to the sterility of the drug products due to insufficient control over the manufacturing environment.

Observation 2 notes that the firm did not adequately validate the sterilization process for equipment utilized in the production of sterile drug products. This deficiency raises concerns about the effectiveness of the sterilization methods, potentially compromising the sterility assurance of the final products.

Observation 3 highlights that the firm did not conduct thorough investigations into discrepancies and failures encountered during the manufacturing process. This indicates a weakness in the facility's quality system, specifically in its ability to identify root causes of issues and implement effective corrective and preventive actions, which could lead to recurring problems and impact product quality and patient safety.